Kardigan, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Kardigan, a recently IPO'd (June 2026) clinical-stage cardiovascular company, raised $460M gross proceeds and holds $660.7M cash as of June 30, 2026. The company is advancing three late-stage programs: danicamtiv (Phase 2b/3 for genetic DCM, Cohort 1 enrollment complete, Phase 2b topline expected 1H 2027), ataciguat (Phase 2b for CAVS, interim 24-week topline 1H 2027), and tonlamarsen (Phase 2 for acute severe hypertension, topline 1H 2027). Q2 R&D expenses were $56.4M (vs. $35.8M YoY), G&A was $18.9M (vs. $21.3M YoY), and net loss was $116.2M (vs. $57.4M YoY); the increased loss reflects clinical trial acceleration and a $43.5M charge for contingent milestone liabilities.
Why this rating
Early-stage biotech; IPO-funded with strong cash runway. Multiple clinical milestones expected but no product approvals, revenue, or partnerships announced. Routine quarterly disclosure for newly public company.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.